Impact of a tak-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the sugen5416/ hypoxia rat model

HIGHLIGHTS

• who: March and colleagues from the University of Florence, Italy have published the research: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/ hypoxia rat model, in the Journal: (JOURNAL)
• what: Novel therapies must go beyond vasodilatation and start targeting maladaptive vascular and RV remodeling if the authors aim to improve the outcomes in PAH patients and progress toward a cure (Prins et_al, 2019a; Prins et_al, 2019b; Scott et_al, 2021). The authors investigated the therapeutic efficacy of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.